Flu season should return Sanofi to double-digit vaccines growth, CEO says

Sanofi CEO Chris Viehbacher

Thanks to supply limitations in the U.S. that spurred a near-30% drop in adult booster vaccines, Sanofi ($SNY) reported Q2 vaccines sales down 0.4% overall. But its flu business posted big gains, ballooning 18.9% to €59 million ($78.9 million)--and CEO Chris Viehbacher says he expects that trend to continue. The helmsman forecast a "very successful" flu season in the U.S. that would help return the unit to double-digit growth in the second half of this year, noting only that that market was becoming tougher on pricing, Reuters reports. "That bears watching and would be my only point of caution for the future," Viehbacher said (as quoted by the news service). Release (PDF) | Report

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.